Skip to main content

Published locations for First-line fixed-duration ibrutinib+venetoclax shows promise against high-risk CLL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. First-line fixed-duration ibrutinib+venetoclax shows promise against high-risk CLL

User login

  • Reset your password
  • /content/first-line-fixed-duration-ibrutinibvenetoclax-shows-promise-against-high-risk-cll
  • /b-cell-lymphoma-icymi/article/263730/b-cell-lymphoma/first-line-fixed-duration-ibrutinibvenetoclax